SCHEMBL20980809

SCHEMBL20980809

CC(C)(C)c1ccccc1NC(=O)C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.55
GRIN3B O60391 1/20 0.55
GRIN1 Q05586 1/20 0.55
GRIN2A Q12879 1/20 0.55
GRIN2B Q13224 1/20 0.55
GRIN2C Q14957 1/20 0.55
GRIN3A Q8TCU5 1/20 0.55
SIGMAR1 Q99720 1/20 0.55
ALDH1A1 P00352 3/20 0.50
LPAR1 Q92633 1/20 0.47
POLB P06746 2/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.46
ALOX12 P18054 1/20 0.46
KMT2A Q03164 1/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 1/20 0.44
LMNA P02545 2/20 0.43
TDP1 Q9NUW8 2/20 0.41
KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6448297 0.89 ALDH1A1 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5032627 0.87 GRIN2D (0.60) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL4422637 0.84 ALDH1A1 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13382332 0.84 ALDH1A1 (0.51) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30977630 0.84 ALDH1A1 (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL30140772 0.82 GRIN2D (0.55) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5497672 0.81 LPAR1 (0.52) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL11132128 0.80 NPC1 (0.52) ALDH1A1POLBGAAKMT2ARAB9A
SCHEMBL631133 0.79 ALDH1A1 (0.57) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL2093266 0.79 ALDH1A1 (0.58) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10981860-B2 Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-04-20 US disclosed
US-20190135733-A1 CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2019-05-09 US disclosed
CN-1525978-A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases 伊邓药品公司 2004-09-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10981860-B2 Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereof CASP1, CASP14, CASP2 GRIN2D 4136/4885GRIN3B 2526/4885GRIN1 2297/4885
US-20190135733-A1 CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF CASP1, CASP14, CASP2 GRIN2D 4136/4885GRIN3B 2526/4885GRIN1 2297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.